Bringing a whole new dimension to lactose

3D Printing in Pharma 

Tablet production is facing many challenges. Korinde van den Heuvel, product developer at DFE Pharma, explains in this article* the huge potential that 3D printing offers in pharmaceutical manufacturing, from enabling personalised medicine to accelerating the drug development pathway. But in order to embrace this new world of opportunities, we need a deeper understanding of the materials, processes and techniques involved.


New research initiated and supported by DFE Pharma, underlines the benefits of 3D powder bed printed tablets with a blend of lactose monohydrate and pregelatinized starch as main carrier system.


We believe that by pooling our resources and knowledge, industry, innovators and academia can build the common evidence base we need to produce the medicines of the future.

This free whitepaper takes the first steps towards that goal, by sharing the findings of our detailed study of lactose as an excipient in the 3D printing of pharmaceuticals. Carried out in partnership with the Netherlands Organisation for Applied Scientific Research (TNO), the project shows that lactose – and collaboration – can yield results. 

*This article is taken from Pharmaceutical Manufacturing and Packing Sourcer, October 2021, pages 68-70. © Samedan Ltd

Request Bringing a Whole New Dimension to Lactose: Lactose Learnings and Evidence Building on 3D Printing in Pharma

And learn about:

  • The challenges and opportunities: Tablets are the mainstay of pharmaceutical delivery, but people can find them difficult to take and manufacturers face production challenges. 3D printing could be the solution, but only one 3D printed medicine has been FDA-approved so far. So what’s stopping us?
  • Where we stand: Powder bed printing is replacing fused deposition modelling as the 3D printing method of choice in pharmaceuticals. But what is it, how does it work, and what makes it superior? 
  • Preparing for the future: As techniques evolve, a significant data gap is opening up. Why is this happening and how do we address it? Could collaboration be the answer?
  • What we discovered: Working with TNO, DFE Pharma tested 20 lactose grades with the primary objective of developing a lactose with sufficient flow, wetting and binding to be used effectively in the powder bed 3D printing of pharmaceuticals. What were the results and does lactose have a place? 
  • How to collaborate: This free whitepaper takes the first steps towards creating a centralised dataset that we believe will accelerate progress. We intend to continue our research in this area. Will you join us?